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ABBREVIATIONS 
 
Angpt2: angiopoietin 2 
AAV: deno-associated-virus 
CRC: colorectal cancer  
CXCR4: C-X-C chemokine receptor type 4 
DMEM: Dulbecco's Modified Eagle Medium 
EGFR: Epidermal growth factor receptor 
EMT: epithelial-mesenchymal transition 
ERK: extracellular-signal-regulated kinases 
FBS: fetal bovine serum 
FFPE: formalin-fixed paraffin-embeded 
H&E: Hematoxylin and eosin stain  
ICH: immunohistochemistry 
KRAS: Kirsten rat sarcoma viral oncogene homolog  
KRas: protein that in humans is encoded by the KRas gene  
KRas G13D: Kirsten rat sarcoma viral oncogene homolog with Aspartic mutation at codon 13 
KRas G12V: Kirsten rat sarcoma viral oncogene homolog with Valine mutation at codon 12  
KRas WT: KRas wild type 
p: p-value 
PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PTHLH: parathyroid hormone-like hormone 
SDF1α: stromal cell-derived factor 1  
UPA/UPAR: Urokinase-type plasminogen activator system 
VEGFA: Vascular endothelial growth factor A 
WT: wild-type 
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ABSTRACT 
 
Although  all  KRas point mutants are considered to have a similar prognostic capacity, their transformation and 
tumorigenic capacities vary widely. We compared the metastatic efficiency of KRas G12V and KRas G13D 
oncogenes  in an orthotopic colorectal cancer (CRC) model. Following  subcutaneous preconditioning 
recombinant clones of the SW48 CRC cell line (Kras WT) expressing the KRas G12V or KRas G13D allele 
were icroinjected in the mouse cecum. The percentage of animals developing  lymph node metastasis was 
higher in KRas G12V than in KRas G13D mice. Micro, macro and visible lymphatic foci were 1.5-3.0 fold 
larger in KRas G12V than in KRas G13D mice (p<0.05) . In lung,  only microfoci were developed in both 
groups. KRas G12V primar tumors had lower apoptosis (7.0+1.2 vs 7.4+1.0 per field, p=0.02), higher tumor 
budding at the invasion front (1.2+0.2 vs. 0.6+0.1, p=0.04) and a higher percentage of CXCR4-overexpressing 
intravasated tumor emboli (49.8+9.4% vs. 12.8+4.4%, p<0.001) than KRas G13D tumors. KRas G12V primary 
tumors showed Akt activation, and β5 integrin, VEGF-A and Serpine-1 overexpression, whereas KRas G13D 
tumors showed integrin β1 and Angpt-2 oeverexpression. The increased cell survival, invasion, intravasation 
and specific molecular regulation observed in KRas G12V tumors is consistent with the higher aggressiveness 
observed in CRC patients expressing this oncogene. 
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INTRODUCTION 
The high incidence, poor prognosis and metastatic spread of colorectal cancer (CRC) makes this disease the 
second most common cause of cancer death in western countries. Forty percent of colorectal tumors bear 
mutations in the KRas gene, the most frequent being the substitution of Gly (KRas WT) by Val (KRas G12V), 
or Asp, at codon 12 and Gly by Asp at codon 13 (KRas G13D) (1). Most studies investigating the Kras 
oncogene as a prognostic marker do not differentiate  between point mutants and  assume all mutants have a 
similar impact on tumor biology. However, studies in CRC patients, in  animal models and in vitro indicate 
otherwise.  
In CRC, the first studies on the incidence of  KRas mutations in codon 12 suggested that different mutations 
may have a different risk for tumor progression. They found that the prevalence of the different KRas 
oncoproteins varied among adenomas and among Dukes A, B and  C tumors (2). The RASCAL study later 
established the KRas G12V mutation as the most aggressive KRAS mutation, associating it with a higher risk of 
recurrence and death in a large CRC patient cohort (3-5). This finding was later confirmed in a larger series 
(n=4,268) (3-5). Consistently, KRas G12V mutation confers a metastatic phenotype that renders CRC tumors 
more aggressive since the incidence of this mutation was found to be higher in primary tumors and metastases 
of  Dukes C/D than in A/B primary tumors. Moreover, within the Dukes’ D cases, KRas G12V mutations were 
associated with decreased overall survival (2, 6). Distinct Kras oncogene mutations have also shown  different 
transformation capacity in 3T3 fibroblasts in vitro (2, 6). In another study it was seen that 3T3 transformants 
that express KRasG12C and KRas G13D show significant differences in their regulation of survival and 
anchorage-independent growth and in the induction of anoikis in culture (7).  It has also been shown  that these 
two transformants generate different sarcoma tumor types when injected in inmunosuppressed mice (8, 9).  
The known differences in the transformation capacity in vitro and tumorigeneicity in vivo of different KRas 
point mutants led us to hypothesize that specific oncogenic KRAS changes, could also have different metastatic 
capacity. The main aim of this study was to compare the metastagenic capacity of two SW48 human CRC 
recombinant clones, expressing  KRas G12V or KRas G13D mutants, after their subcutaneous preconditioining 
followed by orthotopic implantation  in the cecum.  
 
MATERIALS AND METHODS  
SW48 KRas recombinant clones.The SW48 recombinants expressing heterozygous KRasVal12 (KRas G12V) 
or KRasAsp13 (KRas G13D) oncogenic mutation were generated by homologous recombination using an 
adeno-associated-virus (AAV), as previouly described (10). The mutations are knocked-in in a heterozygous 
fashion and the mutant allele are therefore expressed under the gene’s own promoter. Clones obtained were 
sequenced to verify the presence of the corresponding KRas point mutation. SW48 control cells bearing the 
empty vector (KRas WT; KRas protooncogene) and the KRas G12V or KRas G13D recombinants clones were 
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cultured in DMEM (ref. 10829018, Invitrogen, UK) supplemented with 10% FBS (ref. F2442, Sigma-Aldrich, 
St Louis, USA), 50 units/ml penicillin and 50 mg/ml streptomycin (re. 15140122, Invitrogen). 
Generation of the SW48 metastatic colorectal cancer models.We used five-week-old Swiss female nu/nu 
mice weighing 18 to 20 g (Charles River,L-Abreslle, France) for all in vivo experiments. Mice were housed in a 
sterile environment with bedding, water and γ-ray-sterilized food ad libitum. Experiments were approved by the 
Animal Ethics Committee at  Hospital de la Santa Creu i Sant Pau.  
In a preliminary study, we injected the SW48 recombinants expressing KRas G12V or KRas G13D directly into 
cecum. Due to the low metastatic rate we used subcutaneous preconditioning before orthotopic injection. This 
procedure was developed for colorectal cancer models that increase the metastatic rate without changing the 
pattern of metastases (11).  This approach provided a sufficient rate of metastasis to compare metastatic 
development and regulation between KRas G12V- and KRas G13D-derived models.  
 
Briefly, five mice were subcutaneously injected with 2x107 control SW48 cells or 2x107 recombinant cells 
(KRas G12V or KRas G13D) in DMEM, in two flanks. Tumors were excised  when they reached a volume of 
700 mm3 and disaggregated. A cell suspension (2×106 cells re-suspended in 50 µl) derived from SC tumors was 
injected directly into the mouse cecum wall in control (KRas WT, n=9) and KRas G12V (n=11) and KRas 
G13D (n=7) mice using the orthotopic cell microinjection procedure (12). Mice were followed up once a week 
and sacrificed when had lost 10% of their body weight or showed signs of pain or illness. 
 
Necropsy and histopatological  analysis of  primary tumor and metastases. At death, complete necropsy 
examination of each animal was performed. We recorded the presence and size of  the primary tumor and any 
visible metastasic foci. Local tumor and the organs with expected metastases (lymph nodes, liver and lung) 
were removed, collected and processed for the histopathological analysis and  molecular studies as described 
previously (12) .  
Histopathology of primary tumor and all targeted metastatic organs was analyzed by two independent observers 
in stained H&E samples using 4x-20x magnification.  We counted the number and area of micro- and 
macroscopic tumor foci in the affected organs using CellD Olympus software (v3.3).  Foci with a diameter of 
1mm or larger, occupying an area >750000 mm2 (13) were considered  macroscopic. All smaller  foci were 
considered microscopic.  
In primary tumors, we recorded the degree of differentiation and cell morphology, the percentage of tumor 
necrotic area, the apoptotic and mitotic rate,  and the tumor invasion. The apoptotic rates were calculated by 
counting  the number of apoptotic figures in ten ramdomly selected 400x field sections stained with HE. The 
primary tumor invasive capacity was analysed as previously described (11).  Briefly, after anti-A1/A3 keratin 
staining, we counted the number of keratin positive single epithelial tumor cells as well as  tumor cell clusters 
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containing ten or less cells (tumor budding) at the primary tumor front. We recorded the number of keratin 
positive cells or clusters in 3 different tumor fields (400x magnification) for each group.   
 
Molecular analysis of primary tumors and metastatic foci. Molecular analysis was performed using  
immunohistochemistry (IHC) on formalin-fixed paraffin-embeded (FFPE) tumor tissue. IHC staining was 
performed using the DAKO Autostainer automated Link48 (Dako, California,USA) and standard procedures. 
Samples were incubated with the corresponding primary antibody using the following dilutions: integrin β1, β2, 
β3, β4, β5, α1, α2, α3, α4, α5, α6 and αv (1:100. Ref. ECM440. Chemicon, Atlanta, USA),  AKT-p (1:10. Ref. 
M3628, Dako), ANGPT2 (1:50. Ref.  AP10103b Abgent, San Diego, USA), MAPK-P (1:100. Ref. 4676, Cell 
Signaling, Danvers, MA, USA), P-MAPK-38 (1:100. Ref. 9211S, Cell signalling), Vimentin (1:300. Ref.  
M0725, Dako), PTHLH (1:50 Ref.  ABIN394303, Abgent), VEGFA (1:1000. Ref.  ab46154, Abcam, UK), 
beta-catenin (1:300. Ref.  M33539, Dako), serpine1 (1:750. Ref ab28207.  Abcam ), CXCR4 (1:300, Abcam 
(clone UMB2; #3108-1)), anti-A1/A3 keratin (1:100. Ref.  M7003, Dako), CD34 (ready to use, Ref. IR632, 
Dako), E-cadherin  (1:400. Ref. 610182, BD Transduction Laboratories, New Yersey, USA), which were 
followed by incubation with mouse or rabbit secondary antibodies (EndVision, DAKO). We next incubated the 
preparation with DAB substrate (DAKO) for 5 min, and contrasted thiswith hematoxylin. Immuhistochemical 
slides were evaluated by two independent observers who quantified the percentage of stained cells in relation to 
the total number of tumor cells, and their staining intensity (between 0 and 3, where 3 represented the maximum 
intensity). Finally, the multiplication of both values represented the expression of the protein in each sample.  
ELISA assays were performed to determine VEGF-A in primary tumor samples extracts following the 
manufacturer’s recommendations (eBioscience Human VEGF-A Platinum ELISA, ref. BMS277/2CE for 
VEGFA).  
Statistical analysis. Fisher’s  exact test was used to analyze possible significant differences between groups in 
primary tumor or metastasic  rates. The Mann-Whitney test was used to compare tumor size, the number of 
apoptotic or mitotic figures, single tumor cells, and tumor clusters or metastatic foci between groups. 
Differences in survival between groups were evaluated using Kaplan-Meier curves and the Log-rank test. All 
quantitative values were expressed as mean±SE and the statistical tests were performed using SPSS version 
11.0 (IBM, New York, USA). Differences between groups were considered significant at p <0.05.  
 
RESULTS   
 
KRas G12V or KRas G13D expression yields higher metastatic rate and aggresiveness than wild type 
KRas .Mice bearing KRas G12V or KRas G13D onocogene expressing tumors had shorter survival than the 
KRas WT group (190±20 days, p=0.04 for KRas G12V, 188± 36 days for KRas G13D and 265±18 days for 
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KRas WT, p< 0.001).  The take rate was 33% (3/9) in the KRas WT group, 73% (8/11) in the KRas G12V 
group and 57% (4/7) in the KRas G13D group.  These differences were not significant (Table 1). Mean primary 
tumor volume  at necropsy was significantly higher in both KRas G12V (1,201±83 mm3, p<0.05) or the KRas 
G13D (1,395±118 mm3, p<0.01) groups than in KRas WT mice (964±23 mm3). Consequently, KRas mutants 
groups led to mouse death from intestinal obstruction earlier than in the KRas WT group. All groups developed 
undifferentiated stage IV tumors, with 40-70% necrosis and a high degree of vascular invasion.  
Related to metastatic dissemination, all three groups developed lymphatic and lung metastases (Figure 1, Table 
1), whereas no liver metastases were recorded in any group.  The number of mice developing lymph node 
metastases was also higher in KRas G12V (73%) and  KRas G13D (29%) than in KRas WT (11%) mice. 
Moreover, there was a significantly higher number of lymph node metastatic foci in KRas G12V (n=26) or 
KRas G13D (n=41) than in KRas WT mice (p<0.05).  Similarly, the number of lung metastases in KRas G12V 
(n=34) and  KRas G13D (n=27) was significantly higher than in KRas WT (n=10) mice (Table 1)  
 
KRas G12V showed higher tumor cell survival, invasion and CXCR4 expressing intravasated tumor 
emboli than KRas G13D.    We analyzed the number of apoptotic and mitotic cells in H&E sections derived 
from KRas G12V and KRas G13D primary tumors. KRas G12V primary tumors displayed a significantly 
(p=0.02) lower number of apoptotic figures per field (7.0+ 1.2) than KRas G13D tumors (7.4+1.0) (Fig. 2A,B). 
Analysis of the mitotic rate showed a trend towards a higher number of mitotic figures in KRas G12V (4.9+0.5) 
than in KRas G13D (2.8+0.4) primary tumors but they did not reach statistical significance (not shown). In 
contrast to the observations in primary tumors, the mitotic and apoptotic parameters in KRas G12V and KRas 
G13D metastatic foci displayed no significant differences between groups (not shown).  
We also analyzed the invasion front in the primary tumors. We  counted the number of single tumor epithelial 
cells and the number of tumor buds (Figure 2C,D). The number of tumor buds (clusters of ten or fewer  tumor 
cells) in the primary tumors (white arrows Fig. 2C) of the KRas G12V group was significantly (p=0.04) higher 
than the number of clusters (1.2±0.2/field) in the KRas G13D group (0.6±0.1/field) (Fig. 2D,G). In contrast, the 
number of single epithelial tumor cells at the invasion front was not significantly different between groups.  
 
Based on the established relationship between the induction of epithelial mesenchymal transition (EMT) in 
tumor cells and the acquisition of an increased invasive and metastatic capacities (14), we studied the 
expression of Snail-1, as a molecular marker of EMT and the expression of E-cadherin (downregulated during 
EMT) and beta-catenin (upregulated during EMT) in the primary tumors, especially at their invasion front, of 
both groups. We found no differences in Snail-1, E cadherin and beta catenin expression between KRas G12V 
and KRas G13D groups (data not shown).  
To assess differences in intravasation capacity and CXCR4 expression, we counted the number ot tumor emboli 
inside blood vessels in the tissues adjacent to the primary tumors (Figure 2) and performed a CXCR4 
inmunostaining. We observed no significant differences in the number of intravasated tumor emboli in the 
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submucosal and pericolic layers of the cecum between groups. The percentage of tumor cells with CXCR4 
membrane expression in intravasated tumor emboli of KRas G12V mice (49.8+9.4%) was significantly 
(p<0.001) higher than in KRas G13D (12.8+4.4%)intravasated tumor emboli (Figure 2E,F,H). 
 
KRas G12V promotes a higher growth rate in lymph node metastases than KRas G13D mice. We 
analyzed the number of  lymphatic and lung metastasis, determining their size and classified them into micro-, 
macro- and visible metastases. Regarding lymphatic metastasis, the percentage of affected mice was 
significantly higher in KRas G12V (73%, 8/11) than in KRas G13D (23%, 2/7) mice (Figure 1, Table 1). 
Moreover, in KRas G12V mice the mean area of lymphatic microfoci (30.3±8.3 x104um2) was significantly 
(p=0.02) larger than in KRas G13D mice (12.1±2.8 x104µm2). The mean area of the lymphatic macrofoci in 
KRas G12V mice (193.2±28.6x104µm2) was also larger than in KRas G13D mice (158.5x104um2). Similarly, 
the mean area of visible lymphatic metastases in KRas G12V mice (7,523±1,937 x104µm2) was significantly 
(p=0.05) larger than in KRas G13D mice (2,622±400 x104µm2) (Figure 1, Table 1). Thus, as compared to KRas 
GD13, the expression of the KRas G12V oncogene increased lymph node colonization and increased metastatic 
foci growth in lymph nodes by promoting the transition form micro- to macrometastases and from macro- to 
visible metastases. Regarding the development of lung metastasis, there were no significant differences in the 
number of affected mice between KRas G12V and KRas G13D groups. The analysis of metastatic size showed 
only  micrometastasis in KRas G12V or KRas G13D mice. The total number of lung metastases in KRas G12V 
mice (n=34) was higher than in KRas G13D mice (n=27). The mean size of the lung microfoci was significantly 
(p<0.001) larger in KRas G13D (11.9±3.8 x104µm2) than in KRas G12V mice (6.4±1.5 x104µm2) (Table 1, 
Figure 1). No hepatic metastases were observed in SW48-derived KRas WT, KRas G12V or KRas G13D mice.   
 
KRas G12V and KRas G13D induced different molecular changes in primary tumors. The differences in 
metastatic dissemination between the KRas G12V and KRas G13D groups triggered the analysis of the 
expression and/or activation of proteins involved in signalling downstream of KRas (PI3K and MAPK 
pathways) as well as regulators of survival, adhesion, invasion and metastatic dissemination to unveil some of 
the molecular changes that could underlie the observed differences in metastatic dissemination.   
KRas G12V primary tumors showed a modestly (p=0.05) higher activation of PI3K pathway than KRas G13D 
tumors (Figure 3) measured by the level of phospho-AKT. Nevertheless, in lymphatic and lung metastasis, there 
were no significant differences in AKT activation between the KRas G12V and KRas G13D groups. The 
activation of the Erk pathway, as measured by p-MAPK, showed a trend towards a higher activation in KRas 
G12V versus KRas G13D tumors (data not shown). No significant differences were recorded in the activation 
of the Erk pathway in lymph node or lung metastasis between  KRas G12V and KRas G13D groups (data not 
shown).  
To analyze whether the KRas G12V and KRas G13D oncogenes differentially regulated adhesion, we evaluated 
the  expression of α (1, 2, 3, 4, 5, 6 and ν) and β (1, 2, 3, 4, 5 and 6) integrins by IHC.  Of the 13 evaluated 
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integrins, only β5 and β1 showed a differential expression pattern between groups.  The level of β1 integrin 
expression was significantly (p=0.039) higher in KRas G13D primary tumors than in KRas G12V tumors 
(Figure 4A,B).  In contrast, the expression of β5 integrin was higher in the KRas G12V primary tumor than in 
KRas G13D tumors (p = 0.037, Figure 4G,H). In addition, the level of β5 or β1 integrin expression was low in 
both lymph node and lung metastases in the KRas G12V and KRas G13D groups. We did not therefore detect 
significant differences in the expression of these integrins in metastases between groups (Figure 4C-F, 4I-L).  
We did not observe expression of CXCR4 in the bulk of primary tumors or their invasive front in KRas G12V 
and KRas G13D groups. However CXCR4 was expressed in a subset of cells in metastatic foci involving the 
lymph nodes, or lung metastasis. The percentage of tumor cells that overexpressed CXCR4 in their membrane 
in the metastases affecting the lymph nodes in KRas G12V mice was significantly (p=0.009) higher than that in 
KRas G13D mice (Figure 5). There were no significant differences between groups in CXCR4 expression in 
lung metastases. We also evaluated the expression of Serpine-1, a regulator of adhesion and invasion. The 
expression of Serpine-1, as measured by IHC, was significantly (p=0.033) higher in KRas G12V than in KRas 
G13D primary tumors. These differences in expression were not maintained at the metastatic sites. Thus, no 
significant differences in Serpine-1 expression in lymphatic metastases were found between KRas G12V and 
KRas G13D groups. In contrast, the expression of Serpine-1 in lung metastases was significantly (p<0.001) 
higher in KRas G13D than in KRas G12V mice (Figure 5).  
In primary tumors, the expression of VEGFA measured by ELISA, showed  significantly higher (p=0.025)  
levels in KRas G12V than in KRas G13D. We also used immunohistochemistry to detect VEGF-A expression 
in metastatic foci.  We observed no significant differences in lymphatic  metastatic foci between groups. In 
contrast, lung metastases in the KRas G13D group showed a significantly (p<0.001) higher level of VEGF-A 
expression in KRas G13D than in KRas G12V lung metastases (Figure 6). Angiopoietin-2 (Angpt2) is involved 
in angiogenesis and metastatic spread. The analysis of its expression by IHC showed  that Angpt2 was 
significantly (p=0.022) higher in KRas G13D than in KRas G12V primary tumors. The observed differences in 
Angpt2 expression were also maintained in metastases, since KRas G13D displayed  a significantly higher level 
of this protein in metastatic foci involving lymph nodes (p=0.048) and  the lung (p <0.001) than in the KRas 
G12V group. The level of Angpt2 expression in lymph node metastases that developed in the KRas G13D 
group was significantly higher (p=0.045) than that observed in KRas G13D primary tumors (Figure 6). 
Subcutaneous SW48 KRas G12V or SW48 KRas G13D tumors used to generate the metastatic orthotopic 
model mostly exhibited protein expression levels simlar to those found in the derived primary tumors (data not 
shown). These expression profiles differed  from those that we were able to obtain  from cell recombinants 
cultured in vitro. Therefore, most molecular changes appear to be induced during their subcutaneous passage. 
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DISCUSSION    
 
KRas G12V enhances metastases to lymph nodes, an indication of its higher aggresiveness. Our aim was to 
evaluate whether there were differences in metastatic dissemination between SW48-derived mouse CRC 
models expressing the KRas G12V or the KRas G13D oncogene. We observed that the KRas G12V mutation 
increased the percentage of mice with lymph node metastases and also the area of lymphatic microfoci, 
macrofoci and visible lymph node metastases, as compared to KRas G13D. Therefore, the KRas G12V 
oncogene increased both the colonization of the lymph nodes and the growth rate of the metastatic foci at this 
site, promoting the transition from microfoci to large metastases. Our observation of the significantly higher 
capacity for KRas G12V expressing tumor cells to develop  lymphatic metastases suggests higher tumor 
aggresiveness for this mutation. This argument is consistent with the presence of lymph node metastasis as the 
strongest predictor of poor prognosis in CRC patients (15). Moreover, the higher agressiveness observed in 
KRas G12V mice is consistent with the shorter overall survival observed in  CRC patients with KRas G12V 
mutation compared to other Kras mutations, in the RASCAL study (3). In  human CRC tumors, of twelve 
different point mutations found at KRas codon 12 or 13, only the KRas G12V mutation  conveyed an increased 
risk of recurrence and death (3, 4). In another study, an analysis restricted only to Dukes’ D patients showed 
that KRas G12V decreased overall survival as compared to  other KRas mutations (6). In our study,  we did not 
detect any difference between KRas G12V and KRas G13D mice regarding the percentage of  animals with 
lung metastases. KRas G13D seems to stimulate the growth of the lung metastasis more than KRas G12V, but it 
does not appear to be able to induce the transition from micro- to macro-metastases,  since all metastases 
remained microscopic both in KRas G13D and KRas G12V mice. In liver, we did not observe any metastatic 
dissemination, because the SW48 CRC cell line does not show an intrinsic ability to metastasize to the liver. 
We used the SW48 CRC cells because they bear the Kras wild type as well as because they have previously 
been reported to be amenable to genetic engineering by homologous recombination.  
 
KRas G12V alters protein regulation and induces higher tumor cell survival, invasion and intravasation. 
KRas G12V and KRas G13D tumors presented differences in protein expressions involved in invasion, cell 
survival and intravasation processes. KRas G12V enhanced cell survival, invasion and intravasation and 
overexpressed CXCR4, β5 integrin, VEGF-A and Serpine-1, and overactivated Akt in primary tumors. These 
alterations may underlie the increased metastatic growth in the lymph nodes found in KRas G12V mice, as 
compared to KRas G13D. In agreement, the different ras mutants show markedly different transformation 
capacities (16, 17) and  have been associated with different interaction with the downstream effectors (18). In 
our model, KRas G12V induced  activation of the AKT pathway and showed a lower number of apoptotic 
markers in comparison to KRas G13D. It has been shown that the Ras Val12 oncogene activates the PI3K/Akt 
pathway (19, 20), whereas tumors use PKB/Akt pathway activation to inhibit apoptosis, leading to higher 
 11 
migratory, invasive and metastatic capacities (21, 22). Consistently, we previously showed that the KRas G13D 
oncogene displays lower transformation capacity in fibroblasts , associated with Akt inactivation and increased 
apoptosis in vitro (7) and in vivo (8). Consequently, the KRas G13D oncogene  yielded  more indolent 
sarcomas than fibroblasts tranformed with the KRas Cystine 12 (KRas G12C), the expression of which was  
associated with Akt activation and less apoptosis. The activation of the Akt pathway has also been observed in 
stage II CRC patients where AKT activation predicts tumor recurrence (23).  
We also observed that KRas G12V enhanced budding in primary tumors associated with enhanced lymph node 
metastases. In agreement with this finding, in CRC patients, tumor budding at the invasive front is associated 
with lymph node metastases and poor prognosis (24-28).  
The increase of invasion observed in KRAS mutant tumors could be caused by several distinct molecular 
mechanisms.  We discarded epithelial-mesenchymal transition (EMT) as responsible for the enhanced 
metastases observed in KRas G12V since we did not observe differences in single cell count, or in Snail-1, E-
cadherin or β-catenin expression between KRas G12V and KRas G13D tumors at the invasive front, 
characteristic of EMT (14). Nevertheless, in CRC models, several reports support higher migratory and 
metastatic capacity for tumors that overexpress β5 integrin together with Akt activation (observed in our KRas 
G12V tumors) compared to tumors with β1 expression and Akt inactivation (observed in KRas G13D tumors). 
Similarly, migration of the SW480 CRC cell line (which expresses KRas G12V) in type I collagen is dependent 
on αvβ5 expression and Akt activation(29). In contrast, downregulation of αvβ5 integrin in this model leads to 
α2β1-dependent and Akt-independent migration, supporting a cross-regulation between β5 and β1 asosociated 
with differential Akt regulation(29). Moreover, αvβ5-dependent  migration on vitronectin has been associated 
with enhanced liver metastases in the LM-LM6 CRC model, whereas Akt inactivation blocked this migration 
(30). Consistently, the KRas G12V oncogene mutation induces β5 expression and blocks integrin β1 expression 
in colon epithelial cells (31). 
 
Serpine-1 is also overexpressed in KRas G12V tumors and  may contribute to their enhanced invasiveness and 
metastases. Thus, in CRC patients, Serpine-1 overexpression in primary tumors is associated with lymph node 
metastasis (32), whereas high levels of Serpine-1 in plasma is a marker of poor prognosis (33). In addition, 
crosstalk between β5 and β1, like that  described in CRC models,  has been reported in fibroblasts, in which 
integrin β5 degradation leading to β1 upregulation is controlled by uPA/uPAR system activation (34). This 
system is inactivated by serpine-1-. This suggests that Serpine-1, a protein overexpressed together with β5 
integrin in KRas G12V tumors, may regulate this crosstalk in our CRC model, when serpine-1 covalently binds 
to and inactivates the uPA/uPAR system.  
In KRas G12V mice, we observed an increased percentage of CXCR4-overexpressing cells in intravasated 
tumor emboli in the submucosal and pericolic layers of the cecum. We also found also a higher number of 
CXCR4 cells in lymph node metastases. These findings suggest the CXCR4 receptor plays a role  in 
intravasation, enhancing lymph node metastases in our model. This suggestion is in agreement with the 
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association between intravasated tumor emboli (35) and lymphovascular invasion (36) with lymph node 
metastasis and poor prognosis in CRC patients. Similarly, CXCR4  overexpression in primary tumors increased 
the risk of recurrence and poor survival (37) in CRC patients. Moreover, expression of CXCR4 in the HT29 
CRC model favours tumor cell extravasation (38), whereas CXCR4 expression promotes the growth of CT-26 
CRC micrometastases in the colonized organ (39). In addition, CXCR4+ HT29 CRC cells are capable of 
establishing a paracrine signaling with SDF1α secreting lymph node stromal cells (40) which may drive their 
dissemination towards this metastatic site. Similarly, CXCR4 expressing tumor cells are able to migrate through 
hypoxic SDF1α,  secreting endothelial cells (transendothelial migration) and invade blood vessels in a breast 
cancer model (41).  
In agreement with enhanced VEGF-A tumor expression and lymph node metastases observed in KRas G12V 
mice, VEGF-A and CXCR4 are associated with lymph node metastasis and poor prognosis in CRC patients (42-
44). Similarly, in the CT26 CRC model, VEGF-A induces angiogenesis and promotes vascular permeability,  
leading to metastasic spread (45, 46). Finally, and in contrast with  the reports on KRas G12V disregulated 
proteins, no publications on the prognostic value in CRC patients have been reported for the proteins 
overexpressed in KRas G13D tumors (integrin β1 or Angpt-2).   
 
Differential protein regulation in KRas G12V and KRas G13D mice between primary tumors and 
metastases.Whereas protein expression in primary tumors may contribute to determine the mechanism of 
invasion and intravasation, such  expression in metastases may indicate the pathway  used for metastatic foci 
growth at the metastatic site. In our model, KRas G13D tumors overexpressed Angpt-2 and developed larger 
lung micrometastasis than with KRas G12V.  In this regard,  Angpt-2 expression in the primary tumor may have 
promoted colonization of the lung, because it enhances cancer cell extravasation by loosening the endothelial 
cell junctions,  leading to increased metastasis in the lung (47, 48). In contrast, the high levels of Angpt2 
observed in lung microfoci in KRas G13D mice may have determined the inability of  these tumor cells to 
promote vacularization.  It has been observed that  high levels of Angpt-2 induce  microvessel regression and 
tumor growth inhibition in the HT29 subcutaneous CRC model (49).  
The oncogene expressed in primary tumors (KRas G12V or KRas G13D) may determine the pattern of protein 
expression. Interestingly, the pattern of protein expression we found in orthotopic primary tumors was already 
present in the subctutaneous tumors used for KRas G12V and KRas G13D preconditioning. Thus, both 
orthotopic and subcutaneous tumors that expressed KRas G12V showed higher Akt activation and integrin β5 
overexpression than KRas G13D. However, the environment in the site where the tumor grows may also 
contribute to regulate protein expression in tumor cells. In contrast with our observations in primary tumors, the 
number of mitotic and apoptotic figures in KRas G12V and KRas G13D metastatic foci did not differ  
significantly between groups. Therefore,  different metastatic organs appear to regulate apoptosis in a different 
way. We also  observed that the pattern of protein expression in metastases differed greatly from the 
corresponding pattern in the primary tumor. This suggests that that the tumor environment also contributes to 
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determining  this pattern.  In support of this suggestion we observed that VEGF-A or Serpine-1 were  
overexpressed in KRas G12V but not in KRas G13D primary tumors. In lung metastases, these two proteins 
were  overexpressed in KRas G13D compared to  KRas G12V mice.  
 
Clinical implications. In summary, this is the first report to describe a different metastatic capacity and a 
pattern of protein expression for distinct KRas point mutations in an orthotopic mouse CRC model, as well as 
an association between metastatic capacity and CXCR4-overexpressing tumor emboli. Our results have 
highlighted the need to consider the  different KRas mutants as separate entities.    
These results are consistent with the higher aggressivenes of KRas G12V mutant observed in CRC patients, as 
compared to any other KRas mutation and support the notion that different KRas mutants may associate with 
different prognosis. The different regulation of cell survival and Akt-p between KRas G12V and KRas G13D in 
our model may also indicate different responses between KRas G12V and KRas G13D to antitumor drugs. This 
is in agreement with the reported lack of Akt activation by KRas G13D (7, 8), and  with  the higher sensivity of 
KRas G13D CRC cells, as compared to KRas G12V, to the EGFR inhibitor cetuximab in vitro and longer 
overall survival in KRas G13D patients compared with other KRas mutations when being treated with the 
EGFR inhibitor cetuximab (50). However, more recent clinical data are contradictory (51) . Future studies 
should explore other KRas mutations with lower transforming capacity in relation to their ability to engage 
different pathway effectors, their their propensity to metastasize, as well as their impact on anticancer 
treatments. 
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Table 1. Number and area of lymph nodes and pulmonary microfoci. macrofoci and visible metastases 
observed in KRas WT,  KRas G12V and KRas G13D SW48 groups. 
Metastatic dissemination* 
Micro Macro Visible 
Metastatic 
Site 
 
SW48 
Group 
 
 
Affected 
animales 
(n) 
Foci 
(n) 
Area 
mean± SE 
(x105 µm2) 
Foci 
(n) 
Area 
mean± SE 
(x105  µm2) 
Foci 
(n) 
Area 
mean± SE 
(x105  µm2) 
KRas WT 1/9a 0 0c.d 0 0f.g 2 2.486±1754 
KRas G12V 8/11a.b 12 30.3±8.3e.c 4 193.2±28.6f 10 7.523 ±1937h Lymph 
node 
 
KRas G13D 
 
2/7b 27 12.1±2.8e.d 1 158.5 g 13 2.622±400h 
KRas WT 1/9 10 8.9±0.2 0 0 
 
0 
 
0 
 
KRas G12V 4/11 34 6.4±1.5i 0 
 
0 
 
0 
 
0 
 
Lung 
 
KRas G13D 
 
2/7 27 11.9±3.8i 0 0 0 0 
nf: number foci).   
Statistical analysis: a p= 0.03,  b p=0.08 (Test de Fisher,. c p=0.05,  d p=0.028,  e p= 0.02,   f,g p<0.001,  
hp=0.05,   ip<0.001 (Mann Whitney Test) 
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FIGURE LEGENDS 
 
Figure 1. Primary tumor and metastasis development in KRas G12V and KRas G13D mouse models. No 
differences in primary tumor growth were observed between groups (A,B). KRas G12V mice developed micro-, 
macro- and visible-metastasis in the lymph nodes (C), which were significantly bigger than the lymph node 
metastases that developed in KRas G13D mice (D). In contrast, KRasG12D and KRas G13D mice developed 
only microfoci in the lung; however, the lung microfoci in KRas G13D mice were significantly bigger (F) than 
in KRas G12V mice (E). The type of metastasis was established as a function of its diameter: microfoci <1mm; 
macrofoci 1-3 mm; visible >3mm; H&E staining. Original magnification:  x40(C-F) 
 
Figure 2. Reduced apoptosis and increased tumor budding and CXCR4-overexpressing intravasated 
emboli in KRas G12V primary tumors as compared to KRas G13D tumors. Primary tumors in KRas G12V 
mice (A, G) showed a significantly (p=0.019) lower number of apoptotic cells (white arrows) as compared to 
KRas G13D mice (B, G). In contrast, primary tumors in KRas G12V mice (C) showed a significantly (p=0.037) 
larger number of pan-keratin positive tumor clusters (budding) at the invasion front (black arrows), than KRas 
G13D mice (D, G).  Intravasated tumor emboli in the submucosal and pericolic layers of the cecum had a 
significantly (p<0.001) higher percentage of cells overexpressing CXCR4 in KRas G12V (E,H) than in KRas 
G13D primary tumors (F,H). Count of apoptotic bodies, tumor emboli or tumor buds (clusters of 10 or fewer 
cells sourrounded by stroma at the invasive front) was performed in ten 400X magnified primary tumor fields. 
Original magnification : x400 (A-D); x200 (E-F)  
 
Figure 3. KRas G12V primary tumors showed higher AKT activation than KRas G13D tumors.  Primary 
tumors (A) in KRas G12V group showed a significantly (p<0.05) higher level of AKT activation than those (B) 
in the KRas G13D group. No differences in the activation of AKT in lymph node (C,D) or pulmonary (E,F) foci 
were observed between groups (E,F). Original magnification: x200 (A-F) 
 
Figure 4. KRas G12V tumors overexpressed integrin β5, whereas KRas G13D tumors overexpressed 
integrin β1.  Primary tumors (A) in KRas G12V group showed significantly lower β1 integrin expression than 
primary tumors (B) in the KRas G13D group. No expression of β1 integrin was detected in lymph node and 
pulmonary foci in any group (C-F). In contrast, primary tumors (G) in KRas G12V group showed significantly 
higher β5 integrin expression than primary tumous (H) in the KRas G13D group. No expression of β5 integrin 
was detected in lymph node or pulmonary foci in any group (I-L). Original magnification:  x40(A-B); x200(C-
L) 
 
Figure 5. KRas G12V tumors higher levels of Serpine-1 in primary tumors, and of CXCR4 in lymph node 
metastasis, as compared to KRas G13D mice. Primary tumors in KRas G12V mice (A) showed significantly 
higher levels of Serpine-1 expression than primary tumors in KRas G13D mice (B). No differences in Serpine-1 
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expression in lymph node foci were observed between groups (C,D). In contrast, pulmonary foci in KRas G13D 
mice showed significantly higher expression of Serpine-1 than in KRas G12V mice (E,F). Primary tumors in 
KRAS G12V (G) or in KRas G13D (H) lacked CXCR4 expression. However, in lymph node metastases, KRas 
G12V mice showed significantly higher expression of CXCR4 in the membrane than KRas G13D mice (I,J). 
Low level of CXCR4 expression in pulmonary foci of KRas G12V (K) and KRas G13D (L) mice was observed, 
showing no significant differences between groups.  Original magnification:  x200(A-L) 
 
Figure 6. KRas G12V tumors overexpressed VEGFA whereas KRas G13D tumors overexpressed Angpt2. 
Primary tumors in KRas G12V mice showed significant higher expression of VEGFA than in KRas G13D mice 
(A). In contrast, no differences in the VEGFA expression in lymph node foci were observed between groups 
(B,C); whereas in pulmonary foci the expression of VEGF-A was significantly lower in KRas G12V (D) than in 
KRas G13D (E) mice. KRas G12V primary tumors (F) showed significantly lower levels of Angpt2 expression 
than KRas G13D tumors (G). Similarly, lymph node (H,I) or pulmonary (J,K) metastasis in KRas G13D mice 
showed significantly higher Angpt2 expression than KRas G12V mice. Original magnification: x200(C-F);  
x100(G-L) 
 
 
 
 






